NantKwest Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the closing of its initial public offering of 9,531,200 shares of common stock at a price to the public of $25.00 per share, which included 1,243,200 shares sold pursuant to the exercise in full by the underwriters of the offering of their option to purchase additional shares. NantKwest estimates the net proceeds from the offering were approximately $222.5 million after deducting the underwriting discounts and commissions and other offering expenses. Concurrently with the initial public offering, NantKwest also sold 680,000 shares of its common stock in a separate private placement to Celgene Corporation, an existing stockholder, at the initial public offering price, for additional proceeds of $17.0 million.

Help employers find you! Check out all the jobs and post your resume.